as 03-28-2025 4:00pm EST
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | WALTHAM |
Market Cap: | 98.5M | IPO Year: | 2021 |
Target Price: | $9.83 | AVG Volume (30 days): | 437.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.25 | EPS Growth: | N/A |
52 Week Low/High: | $1.34 - $9.69 | Next Earning Date: | 03-05-2025 |
Revenue: | $2,816,000 | Revenue Growth: | -86.62% |
Revenue Growth (this year): | 32.21% | Revenue Growth (next year): | 118.35% |
TCRX Breaking Stock News: Dive into TCRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Simply Wall St.
23 days ago
Zacks
24 days ago
GlobeNewswire
24 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
Zacks
3 months ago
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.